tegoprazan + metronidazole + tetracycline + bismuth

A combination of **tegoprazan** (a potassium-competitive acid blocker), **metronidazole** (an imidazole antibacterial and antiprotozoal agent), **tetracycline** (a broad-spectrum tetracycline antibiotic), and **bismuth** (a mucosal protective agent) used as a **bismuth-based quadruple therapy primarily for the eradication of *Helicobacter pylori* infection**. Tegoprazan provides robust and sustained gastric acid suppression, increasing antibiotic efficacy by maintaining a higher gastric pH. Bismuth acts as a mucosa-protective agent and enhances antibacterial activity. Metronidazole and tetracycline target *H. pylori* through distinct antibacterial mechanisms, reducing resistance risk. This combination is used especially as a second-line or rescue regimen when standard therapies fail or in areas of high antibiotic resistance[1][4].

Brand names

tegoprazan + metronidazole + tetracycline + bismuth

Other names

tegoprazan-based bismuth quadruple therapyTBMTtegoprazan-containing quadruple therapy